145 related articles for article (PubMed ID: 20427868)
1. The role of oral L-carnitine therapy in chronic hemodialysis patients.
Sabry AA
Saudi J Kidney Dis Transpl; 2010 May; 21(3):454-9. PubMed ID: 20427868
[TBL] [Abstract][Full Text] [Related]
2. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients.
Kadiroglu AK; Yilmaz ME; Sit D; Kara IH; Isikoglu B
Ren Fail; 2005; 27(4):367-72. PubMed ID: 16060121
[TBL] [Abstract][Full Text] [Related]
3. Relationship between insulin resistance and erythropoietin responsiveness in hemodialysis patients.
Abe M; Okada K; Soma M; Matsumoto K
Clin Nephrol; 2011 Jan; 75(1):49-58. PubMed ID: 21176750
[TBL] [Abstract][Full Text] [Related]
4. Oral carnitine supplementation for dyslipidemia in chronic hemodialysis patients.
Naini AE; Sadeghi M; Mortazavi M; Moghadasi M; Harandi AA
Saudi J Kidney Dis Transpl; 2012 May; 23(3):484-8. PubMed ID: 22569432
[TBL] [Abstract][Full Text] [Related]
5. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
[TBL] [Abstract][Full Text] [Related]
6. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
Nakamoto H; Mimura T; Honda N
Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
[TBL] [Abstract][Full Text] [Related]
7. Maintenance of elevated versus physiological iron indices in non-anaemic patients with chronic kidney disease: a randomized controlled trial.
McMahon LP; Kent AB; Kerr PG; Healy H; Irish AB; Cooper B; Kark A; Roger SD
Nephrol Dial Transplant; 2010 Mar; 25(3):920-6. PubMed ID: 19906658
[TBL] [Abstract][Full Text] [Related]
8. Lymphocyte 5'-nucleotidase and aminopeptidase N activity in patients on maintenance hemodialysis treated with human recombinant erythropoietin and 1-alpha-D3.
Stefanovic V; Mitić-Zlatkovic M; Radivojevic J; Vlahovic P
Ren Fail; 2005; 27(3):283-8. PubMed ID: 15957544
[TBL] [Abstract][Full Text] [Related]
9. Hemoglobin targets and blood transfusions in hemodialysis patients without symptomatic cardiac disease receiving erythropoietin therapy.
Foley RN; Curtis BM; Parfrey PS
Clin J Am Soc Nephrol; 2008 Nov; 3(6):1669-75. PubMed ID: 18922988
[TBL] [Abstract][Full Text] [Related]
10. [Combined therapy with L-carnitine and erythropoietin of anemia in chronic kidney failure patients undergoing hemodialysis].
Wanic-Kossowska M; Kazmierski M; Pawliczak E; Kobelski M
Pol Arch Med Wewn; 2007; 117(1-2):14-9. PubMed ID: 17642201
[TBL] [Abstract][Full Text] [Related]
11. Endogenous plasma carnitine pool composition and response to erythropoietin treatment in chronic haemodialysis patients.
Reuter SE; Faull RJ; Ranieri E; Evans AM
Nephrol Dial Transplant; 2009 Mar; 24(3):990-6. PubMed ID: 18987259
[TBL] [Abstract][Full Text] [Related]
12. The effects of zinc supplementation on serum zinc and cholesterol concentrations in hemodialysis patients.
Chevalier CA; Liepa G; Murphy MD; Suneson J; Vanbeber AD; Gorman MA; Cochran C
J Ren Nutr; 2002 Jul; 12(3):183-9. PubMed ID: 12105816
[TBL] [Abstract][Full Text] [Related]
13. Carnitine reduced erythropoietin dose required and improved cardiac function of patients on maintenance hemodialysis.
Aoki Y; Yamamoto T
Saudi J Kidney Dis Transpl; 2017; 28(3):477-482. PubMed ID: 28540882
[TBL] [Abstract][Full Text] [Related]
14. The effect of L-carnitine supplementation on lipid parameters, inflammatory and nutritional markers in maintenance hemodialysis patients.
Suchitra MM; Ashalatha VL; Sailaja E; Rao AM; Reddy VS; Bitla AR; Sivakumar V; Rao PV
Saudi J Kidney Dis Transpl; 2011 Nov; 22(6):1155-9. PubMed ID: 22089773
[TBL] [Abstract][Full Text] [Related]
15. [Can the treatment with L-carnitine improve the inflammation in chronic hemodialysis patients?].
Grazi G; Meriggioli M; Donati G
G Ital Nefrol; 2004; 21 Suppl 30():S204-7. PubMed ID: 15750986
[TBL] [Abstract][Full Text] [Related]
16. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
Attallah N; Osman-Malik Y; Frinak S; Besarab A
Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
[TBL] [Abstract][Full Text] [Related]
17. The effects of L-carnitine therapy on respiratory function tests in chronic hemodialysis patients.
Bavbek N; Akay H; Uz B; Uz E; Turgut F; Kanbay M; Senes M; Akcay A; Duranay M
Ren Fail; 2010 Jan; 32(2):157-61. PubMed ID: 20199175
[TBL] [Abstract][Full Text] [Related]
18. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
[TBL] [Abstract][Full Text] [Related]
19. The effect of long-term intravenous high dose B-complex vitamins with or without folic acid on serum homocysteine in hemodialysis patients.
Sombolos K; Fragia T; Natse T; Bartholomatos G; Karagianni A; Katsaris G; Christidou F; Bamichas G; Stangou M; Papagalanis N
J Nephrol; 2002; 15(6):671-5. PubMed ID: 12495282
[TBL] [Abstract][Full Text] [Related]
20. Renormalization of high cardiac output and of left ventricular size following long-term recombinant human erythropoietin treatment of anemic dialyzed uremic patients.
Cannella G; La Canna G; Sandrini M; Gaggiotti M; Nordio G; Movilli E; Maiorca R
Clin Nephrol; 1990 Dec; 34(6):272-8. PubMed ID: 2073771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
